JMD 2000, Vol. 2, No. 2
Copyright © 2000 American Society for Investigative Pathology & Association for Molecular Pathology
A Comparative Study of Fibrous Dysplasia and Osteofibrous Dysplasia with Regard to GS
Mutation at the Arg201 Codon
Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis of Paraffin-Embedded Tissues
Akio Sakamoto*,
Yoshinao Oda*,
Yukihide Iwamoto
and
Masazumi Tsuneyoshi*
From the Department of Anatomic Pathology,
*
Pathological Sciences, and the Department of Orthopaedic Surgery,
Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
 |
Abstract
|
|---|
Fibrous dysplasia and osteofibrous dysplasia are both benign
fibro-osseous lesions of the bone and are generally seen during
childhood or adolescence. Histologically, the features of these
bone lesions sometimes look quite similar, but their precise
nature remains controversial. Mutation of the
subunit of
signal-transducing G proteins (GS
), with an
increase in cyclic adenosine monophosphate (cAMP) formation,
has been implicated in the development of multiple endocrinopathies of
the Albright-McCune syndrome and in the development of fibrous
dysplasia. We studied GS
mutation at the
Arg201 codon in seven cases of fibrous dysplasia (six
monostotic lesions and one polyostotic lesion) and seven cases of
osteofibrous dysplasia using formalin-fixed, paraffin-embedded
tissue, by means of polymerase chain reaction-restriction
fragment length polymorphism and direct sequencing analysis. All of the
seven cases of fibrous dysplasia showed missense point mutations in
GS
at the Arg201 codon that resulted in
Arg-to-His substitution in three cases and Arg-to-Cys substitution in
four cases. On the other hand, the seven cases of osteofibrous
dysplasia and the normal bone used as a control showed no such
mutation. These data suggest that fibrous dysplasia and osteofibrous
dysplasia have different pathogeneses and that the detection of
GS
mutation at the Arg201 codon is quite
useful for distinguishing between these lesions.
 |
Introduction
|
|---|
Fibrous dysplasia is a benign intramedullary fibro-osseous lesion
that can occur in any bone. Lichtenstein and Jaffe gave it the name
"fibrous dysplasia" in two classic publications in 1938 and
1942.1, 2
Three forms of fibrous dysplasia are
distinguishable: a monostotic form, a polyostotic form, and a
polyostotic form associated with endocrinopathies and skin
pigmentation, also known as the Albright-McCune
syndrome.3, 4
Histologically, fibrous dysplasia is composed
of slender and curved trabeculae of bone and a cellular proliferation
of fibroblast-like cells, which are characteristically associated with
long bones. Moreover, some cases of fibrous dysplasia also show
sclerotic patterns, particularly in craniofacial bones.5
Mutation of the
subunit of signal-transducing G proteins
(GS
) at the Arg201 codon
stimulating cyclic adenosine monophosphate (cAMP) formation has been
identified in various tissues in the Albright-McCune
syndrome6, 7
and is also thought to underlie the
development of fibrous dysplasia associated with a cellular retraction
and deposition of abnormal bone matrix led by increased cAMP
formation.5, 8, 9, 10, 11
Osteofibrous dysplasia of long bone is a rare fibro-osseous lesion of
unknown pathogenesis described as a distinct entity by Campanacci in
1976.12
Osteofibrous dysplasia is an intracortical lesion
which occurs almost exclusively in the tibia or fibula of children
younger than 10 years of age and often presents as a painless
enlargement of the tibia with anterior or anterolateral bowing.
Histologically, osteofibrous dysplasia is characterized by woven bone
trabeculae with a rimming of osteoblasts and a cellular proliferation
of fibroblast-like cells, and has long been thought to be related to
adamantinoma of long bones.13, 14, 15
Fibrous dysplasia sometimes resembles osteofibrous dysplasia
histologically. Osteofibrous dysplasia has been considered to be a
congenital lesion or a variant of fibrous dysplasia.16
However, the precise nature of fibrous dysplasia and osteofibrous
dysplasia remains controversial. Though GS
mutation in cases of fibrous dysplasia has been extensively studied,
such mutation in osteofibrous dysplasia has not been fully evaluated.
In this study, we investigated the occurrence of
GS
mutation at the
Arg201 codon in both fibrous and osteofibrous
dysplasia with a view to verifying whether the presence or absence of
this mutation can help to distinguish between these two lesions.
 |
Materials and Methods
|
|---|
Specimens
From the histopathology files at our institute, formalin-fixed,
paraffin-embedded tissue blocks of seven cases of fibrous dysplasia and
seven cases of osteofibrous dysplasia, which had been decalcified in
hydrochloric acid for a maximum of 3 days, were used for this study.
The seven cases of fibrous dysplasia comprised six monostotic
lesions and one polyostotic lesion. None of the patients with fibrous
dysplasia exhibited Albright-McCune syndrome. One mature bone specimen
obtained from a donor with neither fibrous dysplasia nor osteofibrous
dysplasia was used for a comparative control.
Formalin-Fixed, Paraffin-Embedded Tissue DNA Extraction
DNA was extracted from a 30-µm paraffin-embedded tissue section
as follows. Paraffin was removed with xylene, and then the sample was
washed twice with 100% ethanol and subsequently dried. The tissue was
suspended in digestion buffer (100 mmol/L sodium chloride, 10 mmol/L
Tris-hydrochloric acid, 25 mmol/L ethylenediaminetetraacetic acid,
0.5% sodium dodecyl sulfate) containing 10 µg proteinase K and
incubated overnight at 55°C. DNA, precipitated by adding twice the
volume of ethanol, was washed with 70% ethanol before being
resuspended in TE buffer (10 mmol/L Tris, 1 nmol/L
ethylenediaminetetraacetic acid) for storage at 4°C.
Polymerase Chain Reaction-Restriction Fragment Length Polymorphism
(PCR-RFLP)
We used the PCR-RFLP procedure to detect
GS
mutations at the
Arg201 codon (CGT) with strategy primers as
reported.17
Table
1summarizes the primers used in this study. DNA sequences containing
codon 201 of the GS
gene were amplified using
the primers P1 and P2 for 30 cycles (95°C for 60 seconds, 55°C for
60 seconds, and 75°C for 60 seconds). Then 1 µl of the amplified
products, which had been diluted 50 times, was amplified by means of
nested PCR using the mutant primer P3 and the primer P2 for 20 cycles
(94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30
seconds), since the primer P3 creates a new restriction site for
EagI (CGGCCG) through the change to G in the first position
of codon 200 in the normal allele, thus enabling the detection of a
mutation at the first and the second positions of the
Arg201 codon. Substitutions for arginine will not
occur even if a point mutation occurs in the third position of codon
201, so this method can be used to detect all of the substitutions for
arginine by other amino acids due to a point mutation. EagI
digests the 102-bp amplified fragment into two fragments of 79 and 23
bp, thereby revealing the presence of the normal allele, while the
mutant allele remains within the undigested 102-bp fragment. Fragments
(134 bp) of p53 gene exon 8 were amplified for 40 cycles
(95°C for 1 minute, 66°C for 1 minute, and 72°C for 2 minutes) as
a positive control to test for the suitability of the respective
material for PCR amplification. The DNA bands were analyzed by 3%
agarose gel electrophoresis, stained with ethidium bromide, and then
photographed.
Direct Sequencing
After samples of the digested products were obtained from agarose
gels and reamplified by primers P3 and P4 for 20 cycles (95°C for 30
seconds and 55°C for 30 seconds), the amplified product was purified
by centrifugal filter devices of Microcon (Millipore, Bedford, MA).
After purification, direct sequencing was carried out by the dideoxy
chain termination method using a Perkin Elmer ABI Prism 310 sequence
analyzer (Perkin Elmer, Foster City, CA). The primer used for direct
sequencing was the antisense primer P4. Because codon 201 is located
next to the 3' end of the sense primer P3, it was not technically
feasible to carry out direct sequencing with the sense primer P3 using
the dideoxy chain termination method.
 |
Results
|
|---|
Table
2summarizes the data. The GS
point mutations at
the Arg201 codon occurred in all seven cases of
fibrous dysplasia, comprising four cases of G-to-A transition in the
first position and three cases of C-to-T transition in the second
position at codon 201, corresponding to the previously reported
Arg-to-Cys and Arg-to-His substitutions respectively. On the other
hand, all seven cases of osteofibrous dysplasia as well as the normal
bone used as a control showed no mutation in the
GS
gene at the Arg201
codon (Figures 1
and 2
).

View larger version (30K):
[in this window]
[in a new window]
|
Figure 2. Direct sequencing by the antisense primer P4 was performed on the
fibrous dysplasia sample in lane 5
(Case FD99; 65-year-old female,
ilium). The figure shows the
GS gene antisense sequence and indicates that
the second position of codon 201 of the antisense strand was mutated
from C to T, this change being the code for histidine instead of
arginine
(right). In
normal bone, sequence analysis was performed after reamplified PCR
without subsequent endonuclease digestion. The result was that arginine
was encoded, and no mutation was seen
(left).
|
|
 |
Discussion
|
|---|
Clinically, fibrous dysplasia differs from osteofibrous dysplasia
with regard to the affected site, affected age group, radiographic
appearance and clinical course (Figures 3
and 4
).15, 18, 19
These findings indicate that fibrous dysplasia
differs in nature from osteofibrous dysplasia. However, because their
histological features are often similar,18
the question of
whether osteofibrous dysplasia is actually a separate entity or
simply a variant of fibrous dysplasia (Figures 5
and 6
) remains controversial.16

View larger version (90K):
[in this window]
[in a new window]
|
Figure 3. Fibrous dysplasia (12-year-old female,
radius). Anteroposterior radiograph reveals a
well-circumscribed intramedullary lesion within the proximal radius
with a so-called "ground glass" appearance
(white
arrows).
|
|

View larger version (100K):
[in this window]
[in a new window]
|
Figure 4. Osteofibrous dysplasia (14-year-old female,
tibia). Lateral radiograph reveals an osteolytic
intracortical lesion in the tibial shaft with marginal sclerosis
(white
arrows). In this case, an intramedullary
lesion that appears to be a bone infarct can be also observed.
|
|

View larger version (131K):
[in this window]
[in a new window]
|
Figure 5. Fibrous dysplasia (15-year-old male,
femur). Slender curved trabeculae of bone and
cellular proliferation of fibroblast-like cells can be observed
(A). Note the
bone trabeculae have no osteoblastic rimming
(B). H&E;
original magnifications, x100
(A) and x140
(B).
|
|

View larger version (184K):
[in this window]
[in a new window]
|
Figure 6. Osteofibrous dysplasia (13-year-old female,
tibia). Microscopic features are characterized
by woven bone trabeculae with rimming of osteoblasts and a cellular
proliferation of fibroblast-like cells. H&E; original magnification,
x140.
|
|
In the present study, we used PCR-RFLP and direct sequencing analysis
to detect the occurrence of GS
mutations at
the Arg201 codon in fibrous dysplasias and
osteofibrous dysplasias using formalin-fixed, paraffin-embedded
decalcified tissue. A variety of techniques has been developed for
detecting GS
mutations. This method of
PCR-RFLP analysis can detect GS
mutations at
the Arg201 codon without using any radioactive
material, even when the mutations are present in low
abundance.17
In addition to the substitution of either Cys or His at
Arg,2015, 11
the substitution of Ser
has also been detected.17
These somatic mutations in the
GS
gene lead to constitutively activated
adenylate cyclase activity,20
elevated cAMP levels, and
increased proliferation of hormonally responsive osteoblastic cells,
resulting in the overproduction of a disorganized collagenous
matrix.5, 8, 9, 10, 11
Thus, both polyostotic and monostotic
fibrous dysplasia seem to result from the abnormal proliferation of
mesenchymal osteoblast progenitor cells with
GS
mutation. On the other hand, the
GS
mutation may stimulate osteoblastic cell
proliferation of early immediate genes, including c-fos. The
products of c-fos proto-oncogene have been associated with
the control of bone cell proliferation and
differentiation.21
The increased production of cAMP in
bone cells with GS
mutations most likely leads
to elevated c-fos expression,22
which also
plays an important part in the development of fibrous
dysplasia.23
There is another possible mutation site in
the GS
gene at Gln227
that has been shown to result in activation. A substitution of either
Leu or Arg at Gln227 has been found in certain
endocrine tumors,24, 25
but has not yet been identified in
association with bone. On the other hand, mutation in the
GS
gene at Gln227 cannot
be ruled out by the analysis that was performed in this study.
Alman et al26
demonstrated GS
mutation in all four of their cases of fibrous dysplasia but not in
their one case of osteofibrous dysplasia. We were also able to detect
GS
point mutations at the
Arg201 codon, comprising substitutions of
Arg-to-Cys or Arg-to-His as others have previously
reported,5, 11
in all our seven cases of fibrous dysplasia,
but not in any of our cases of osteofibrous dysplasia. We cannot deny
the possibility that there were simply not enough mutant cells present
to be detected by this method and that there may be a potential problem
with recovery of an adequate quality of intact DNA due to
decalcification in hydrochloric acid. However, our data support their
conclusion that fibrous dysplasia and osteofibrous dysplasia are
distinct pathological entities with a different molecular pathobiology.
Komiya et al27
surmised that abnormalities in the blood
circulation within the periosteum are probably behind the pathogenesis
of osteofibrous dysplasia. Pathological periosteum may stimulate the
production of excessive osteoclasts. The tumorous condition of
osteofibrous dysplasia can probably be attributed to dysregulation of
bone remodeling, in which osteoclastosis is dominant to osteogenesis.
According to the report of Sweet et al,28
when comparing
fibrous dysplasia and osteofibrous dysplasia, immunohistochemical
staining of cytokeratin (AE1/AE3 + CK-1) seemed to be helpful for
distinguishing between these lesions, because isolated
cytokeratin-positive cells were seen in the stroma of 28 of 30 cases of
osteofibrous dysplasia (93%), but not in any of the 47 cases of
fibrous dysplasia (43 monostotic and 4 polyostotic cases).
Not only the clinical, pathological, and immunohistochemical
differences, but also the presence or absence of
GS
mutations at the
Arg201 codon would seem to suggest that fibrous
dysplasia is a different lesion from osteofibrous dysplasia.
We demonstrated GS
mutation in a series of
fibrous dysplasia and osteofibrous dysplasia using paraffin-embedded
decalcified tissue by means of PCR-RFLP analysis.
GS
mutation at the
Arg201 codon was seen in all of the fibrous
dysplasia cases, but not in any of the osteofibrous dysplasia cases.
Our data suggest that fibrous dysplasia and osteofibrous dysplasia are
of a different pathogenesis. The detection of
GS
mutation at the
Arg201 codon would therefore seem to be quite
useful for distinguishing between fibrous dysplasia and osteofibrous
dysplasia when making a pathological diagnosis.
 |
Acknowledgments
|
|---|
The English used in this manuscript was revised by Miss K. Miller
of the Royal English Language Center, Fukuoka, Japan.
 |
Footnotes
|
|---|
Address reprint requests to Masazumi Tsuneyoshi, M.D., Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 31-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Supported by a grant-in-aid for cancer research from the
Fukuoka Cancer Society, Fukuoka, Japan, and a grant-in-aid for general
scientific research from the Ministry of Education, Science and Culture
(09470052), Tokyo, Japan.
Accepted for publication February 18, 2000.
 |
References
|
|---|
-
Lichtenstein L: Polyostotic fibrous dysplasia. Arch Surg 1938, 36:874-898
-
Lichtenstein L, Jaffe HL: Fibrous dysplasia of a bone: condition affecting one, several or many bones, graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch Pathol 1942, 33:777
-
Arbright F, Bulter AM, Hampton AO, Smith P: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction with precocious puberty in females. N Engl J Med 1937, 216:727-746
-
Danon M, Crawford JD: The McCune-Albright syndrome. Ergeb inn Med Kinderheild 1987, 55:81-115
-
Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Robey PG, Bianco P: The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol 1999, 187:249-258[Medline]
-
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325:1688-1695[Abstract]
-
Shenker A, Weinstein LS, Sweet DE, Spiegel AM: An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994, 79:750-755[Abstract]
-
Schwindinger WF, Francomano CA, Levine MA: Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992, 89:5152-5156[Abstract/Free Full Text]
-
Malchoff CD, Reardon G, MacGillivray DC, Yamase H, Rogol AD, Malchoff DM: An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab 1994, 78:803-806[Abstract]
-
Marie PJ, de Pollak C, Chanson P, Lomri A: Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 1997, 150:1059-1069[Abstract]
-
Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P: Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997, 151:1587-1600[Abstract]
-
Campanacci M: Osteofibrous dysplasia of long bones, a new clinical entity. Ital J Orthop Traumatol 1976, 2:221-237[Medline]
-
Alguacil-Garcia A, Alonso A, Pettigrew NM: Osteofibrous dysplasia (ossifying fibroma) of the tibia and fibula and adamantinoma: a case report. Am J Clin Pathol 1984, 82:470-474[Medline]
-
Keeney GL, Unni KK, Beabout JW, Pritchard DJ: Adamantinoma of long bones: a clinicopathologic study of 85 cases. Cancer 1989, 64:730-737[Medline]
-
Markel SF: Ossifying fibroma of long bone: its distinction from fibrous dysplasia and its association with adamantinoma of long bone. Am J Clin Pathol 1978, 69:91-97[Medline]
-
Park YK, Unni KK, McLeod RA, Pritchard DJ: Osteofibrous dysplasia: clinicopathologic study of 80 cases. Hum Pathol 1993, 24:1339-1347[Medline]
-
Candeliere GA, Roughley PJ, Glorieux FH: Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in G alpha s from patients with fibrous dysplasia of bone. Bone 1997, 21:201-206[Medline]
-
Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M: A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to expressions of c-fos and c-jun products and bone matrix proteins: a clinicopathological review and immunohistochemical study of c-fos, c-jun, type i collagen, osteonectin, osteopontin and osteocalcin. Human Pathol 1999, 30:1418-1426[Medline]
-
Wang JW, Shih CH, Chen WJ: Osteofibrous dysplasia (ossifying fibroma of long bones): a report of four cases and review of the literature. Clin Orthop 1992, 278:235-243
-
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L: GTPase inhibiting mutations activate the alpha chain of Gs, and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340:692-696[Medline]
-
Machwate M, Jullienne A: Temporal variation of c-fos proto-oncogene expression during osteoblast differentiation, and osteogenesis in developing rat bone. J Cell Biochem 1995, 57:62-70[Medline]
-
Gaiddon C, Boutillier AL, Monnier D, Mercken L, Loeffler JP: Genomic effects of the putative oncogene G alpha s: chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells. J Biol Chem 1994, 269:22663-22671[Abstract/Free Full Text]
-
Candeliere GA, Glorieux FH, Prudhomme J, St-Arnaud R: Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 1995, 332:1546-1551[Abstract/Free Full Text]
-
Vallar L: GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours. Biochem Soc Symp 1990, 56:165-170[Medline]
-
Clementi E, Malgaretti N, Meldolesi J, Taramelli R: A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. Oncogene 1990, 5:1059-1061[Medline]
-
Alman BA, Greel DA, Wolfe HJ: Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res 1996, 14:311-315[Medline]
-
Komiya S, Inoue A: Aggressive bone tumorous lesion in infancy: osteofibrous dysplasia of the tibia and fibula. J Pediatr Orthop 1993, 13:577-581[Medline]
-
Sweet DE, Vinh TN, Devaney K: Cortical osteofibrous dysplasia of long bone and its relationship to adamantinoma: a clinicopathologic study of 30 cases. Am J Surg Pathol 1992, 16:282-290[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
C REIS, E M GENDEN, J B BEDERSON, and P M SOM
A rare spontaneous osteosarcoma of the calvarium in a patient with long-standing fibrous dysplasia: CT and MR findings
Br. J. Radiol.,
February 1, 2008;
81(962):
e31 - e34.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Lietman, C. Ding, and M. A. Levine
A Highly Sensitive Polymerase Chain Reaction Method Detects Activating Mutations of the GNAS Gene in Peripheral Blood Cells in McCune-Albright Syndrome or Isolated Fibrous Dysplasia
J. Bone Joint Surg. Am.,
November 1, 2005;
87(11):
2489 - 2494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. DiCaprio and W. F. Enneking
Fibrous Dysplasia. Pathophysiology, Evaluation, and Treatment
J. Bone Joint Surg. Am.,
August 1, 2005;
87(8):
1848 - 1864.
[Abstract]
[Full Text]
[PDF]
|
 |
|